DSM’s Pharma Business Reports Weak Results in First Quarter

6:49 AM MDT | May 8, 2012 | Deepti Ramesh

DSM says that the performance of the company’s pharmaceutical business in the first quarter of 2012 remained weak, although first signs of improvement are visible. The pharmaceutical business reported a 7% rise in first-quarter sales, compared with the year-ago period, to €175 million ($227 million). The business reported an Ebit loss of €8 million in the first quarter compared with an Ebit loss of €10 million in the year-ago period. DSM’s pharma business comprises DSM Pharmaceutical Products and DSM Sinochem Pharmaceuticals, the former...